US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Clinical data on XM-ONE at ASHI supports previously published multicenter study

Improving outcomes in kidney transplantation: Non-HLA antibodies and Enhanced Clinical Risk AssessmentData from two well known US centers was presented during a symposium at the American Society of Immunogenetics and Histocompatibility, held in Hollywood, Florida the last days of September. The meeting, which was chaired by Professor Adriana Zeevi from University of Pennsylvania Medical School in Pittsburgh, focused on the clinical experience of XM-ONE®, an endothelial cell crossmatch for the detection of non-HLA antibodies. Data from Northwestern University Hospital in Chicago as well as

AbSorber strengthens the position on the US market by acquiring Olerup Inc.

AbSorber strengthen its position on the important US market by acquiring NorDiag’s share of Olerup Inc. AbSorber buys the company together with SSP Primers and after the transition will AbSorber own 50 percent of Olerup Inc. and SSP Primers 50 percent.Olerup Inc. is selling the Olerup SSP HLA typing products and AbSorbers transplantation cross match test in the USA. The American market also includes Canada and South America. Olerup Inc. will continue to market and sell NorDiag’s product Arrow on the American market. Olerup Inc today has 7 employees but will be increased as a consequence of

AbSorber receives European patent protection for its transplantation cross match-test XM-ONE®

AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product. The European countries are highly prioritized markets for AbSorber and the patent approval is an important milestone in Absorbers intellectual property strategy.The patent was granted by the European Patent Office (EPO) and AbSorber has also patent applications pending for XM-ONE® in the US, Japan and other key transplantation markets. The company expects

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media